Does CYP have a single point of failure like IIL? Could a single market sensitive ann sink us in the same way it did those schmucks?
I think so. We're casting a wide net across a range of clinical applications but unresolvable gremlins in the underlying tech can still bring the house crashing down at a moment's notice.
These are the perils of biotech. Stop losses are essential. Stink bids are dangerous. Milestones for success are predictable and long term whereas company disclosures re catastrophic failure may always be just seconds away
Ann: Cynata Therapeutics GvHD Clinical Trial & Corporate Progress, page-42
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $42.45M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 24.0¢ | 22.5¢ | $34.16K | 148.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9715 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 49931 | 1 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| CYP (ASX) Chart |